Presbyterian Intercommunity Hospital

Summary

Presbyterian Intercommunity Hospital is a medical facility located in Whittier, California. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer, Colorectal Cancer and other specialties. Presbyterian Intercommunity Hospital is involved with conducting 60 clinical trials across 100 conditions. There are 4 research doctors associated with this hospital, such as Lisa S. Wang, Christopher R. Foss, Lisa Shing-E Lu Wang, M.D., and Edwin Y. Lin.

Top PIs

Clinical Trials running at Presbyterian Intercommunity Hospital

Breast Cancer

Ovarian Cancer

Lung Cancer

Endometrial Cancer

Non-Small Cell Lung Cancer

Breast cancer

Cancer

Fallopian Tube Cancer

Peritoneal Carcinoma

Solid Tumors

Trastuzumab Deruxtecan + Anastrozole

for Breast Cancer

This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels on cancer cells in a targeted way and delivers deruxtecan to kill them. Anastrozole works by decreasing estrogen production and suppressing the growth of tumors that need estrogen to grow. This study is evaluating how effective trastuzumab deruxtecan is at treating hormone receptor positive cancer cells that have low levels of HER2 expressed on them when given alone or in combination with anastrozole.

Recruiting

1 award

Phase 2

21 criteria

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Recruiting

1 award

Phase 2

17 criteria